Walgreens share price down 12% after Q2 earnings revenue miss

The drugstore chain's stock is down after missing Wall Street estimates.

US dollars after Walgreens Q2 results Source: Bloomberg

Walgreens share price is down after weaker-than -expected second quarter (Q2) earnings. Walgreens’ Q2 earnings fell below Wall Street estimates.

Walgreens earnings:key figures

Earnings per share (EPS) $1.64
Revenue $34.53 billion
Net Income $1.16 billion
Sales $26.3 billion
Same store sales -3..8%

Walgreens share price falls 12% as Q2 earnings revenue misses estimates

Walgreens' earnings per share (EPS) was $1.64, below financial analysts’ expectations of $1.72. Walgreens’ revenue was $34.53 billion, slightly under estimates of $34.56 billion. The drugstore chain’s net income declined to $1.16 billion from $1.35 billion. Walgreens Q2 results also disappointed as same-store sales also dropped 3.8%. The only positive statistic was in sales, which rose 7.3% to $26.3 billion after purchasing another drugstore chain, Rite Aid.

Walgreens share price ironically declined because of good health news. A better-than-expected US flu season led to fewer shoppers going to the drugstore chain for cold medicine. Walgreens’ Q2 profits also plummeted because of cheaper generic medication prices.

Chief executive officer, (CEO), Stefano Pessina, noted the challenges affecting Walgreens’ Q2 profits. One issue is lower reimbursement rates for medicine from government health care plans.

‘The market challenges and macro trends we have been discussing for some time accelerated, resulting in the most difficult quarter we have had since the formation of Walgreens Boots Alliance,’ said Pessina.

‘During the quarter, we saw significant reimbursement pressure, compounded by lower generic deflation, as well as continued consumer market challenges in the US and UK,’ added Pessina.

How do Walgreens’ Q2 results compare to other drugstore chains?

Walgreens Q2 results are worse than rival drugstore chain CVS. CVS had positive Q4 results because of higher prescriptions filled at their pharmacies.

What’s next for Walgreens’ Q3 profits?

Pessina said that his expectations for fiscal year 2019 were lowered because of the challenges of generic medicine prices falling. Because of that factor, he expected Walgreens’ earnings to remain flat.

‘While we had begun initiatives to address these trends[of generic medicine prices dropping], our response was not rapid enough given market conditions, resulting in a disappointing quarter that did not meet our expectations,’ said Pessina.

‘As a result, we are now expecting roughly flat adjusted EPS growth for fiscal 2019,’ added Pessina.

Walgreens hopes to revive brand through digitisation

Pessina vowed to improve Walgreens’ profits in the future by speeding up digitisation of their pharmacies to attract more customers. The chain will also sell CBD hemp-based oil products similar to CVS to keep up with customer demand.

‘We are going to be more aggressive in our response to these rapidly shifting trends. We are focusing on our operational strengths and addressing weaknesses, making a number of senior appointments to bring change and accelerating the digitalization and transformation of our business’, said Pessina.


This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
Bid
Offer
Updated
Change
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Bid
Offer
Updated
Change
Bid
Offer
Updated
Change
-
-
-
-
-
-
-
-
-
-
-
-
China 300
-
-
-
-

Prices above are subject to our website terms and agreements. All share prices are delayed by at least 20 minutes. Prices are indicative only.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.